Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis

Lignende værker

• Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
  af: Huang, Ya-fang, et al.
  Udgivet: (2019)
• A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
  af: Dan Chen, et al.
  Udgivet: (2025-08-01)
• FDA‐Approved Biologics for CRSwNP: A Five‐Year Analysis of the FDA Adverse Event Reporting System
  af: Radhika Duggal, et al.
  Udgivet: (2025-10-01)
• Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System
  af: Xuexue Liu, et al.
  Udgivet: (2025-09-01)
• Assessing taxane-associated adverse events using the FDA adverse event reporting system database
  af: Lao, Dong-Hui, et al.
  Udgivet: (2021)